Cargando…
One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
BACKGROUND: This prospective, open-label, non-comparative, multicentre, long-term phase IV study is examining the efficacy and safety of somatropin [recombinant human growth hormone (rhGH)] in short children born small for gestational age (SGA) and its impact on the incidence of diabetes. This repor...
Autores principales: | Schwarz, Hans-Peter, Birkholz-Walerzak, Dorota, Szalecki, Mieczyslaw, Walczak, Mieczyslaw, Galesanu, Corina, Metreveli, David, Khan-Boluki, Jasmin, Schuck, Ellen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254863/ https://www.ncbi.nlm.nih.gov/pubmed/24676989 http://dx.doi.org/10.1007/s13554-014-0014-4 |
Ejemplares similares
-
Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
por: Schwarz, Hans-Peter, et al.
Publicado: (2016) -
Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data
por: Romer, Tomasz, et al.
Publicado: (2011) -
Long-term follow up of carbohydrate metabolism and adverse events after termination of Omnitrope® treatment in children born small for gestational age
por: Walczak, Mieczyslaw, et al.
Publicado: (2021) -
Correlation of Genotype and Perinatal Period, Time of Diagnosis and Anthropometric Data before Commencement of Recombinant Human Growth Hormone Treatment in Polish Patients with Prader–Willi Syndrome
por: Lecka-Ambroziak, Agnieszka, et al.
Publicado: (2021) -
Effects of Recombinant Human Growth Hormone Treatment, Depending on the Therapy Start in Different Nutritional Phases in Paediatric Patients with Prader–Willi Syndrome: A Polish Multicentre Study
por: Lecka-Ambroziak, Agnieszka, et al.
Publicado: (2021)